Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Methotrexate induces remission in refractory Crohn's disease

Research reported in this month's Cochrane Database of Systematic Reviews recommends the use of methotrexate 25 mg intramuscularly weekly for induction of remission and complete withdrawal from steroids in patients with refractory Crohn's.

News image

fiogf49gjkf04

Although corticosteroids are effective for induction of remission of Crohn's disease, approximately 20% of patients who respond relapse when steroids are withdrawn and become steroid dependent.

Furthermore, corticosteroids exhibit significant adverse effects.

The success of methotrexate as a treatment for rheumatoid arthritis led to its evaluation in patients with refractory Crohn's disease.

Methotrexate has been studied for induction of remission of refractory Crohn's disease and has become the principal alternative to azathioprine/6MP therapy.

The evidence for its effectiveness has not been subjected to a systematic review.

Dr Alfadhli and colleagues conducted a systematic review of the evidence for effectiveness of methotrexate for induction of remission with active Crohn's disease.

The researchers looked at active Crohn’s disease in the presence and absence of concomitant steroid therapy.

3 small studies were identified that used low doses of methotrexate orally
The Cochrane Database of Systematic Reviews

The research team conducted a computer-assisted search of MEDLINE and EMBASE for randomized controlled trials involving patients of age more than 17 years.

The team searched for relevant studies published in English, French, Spanish, Italian and German between 1966 and 2004.

Manual searches of reference lists from potentially relevant papers were performed to identify additional studies.

In addition, the researchers searched the Cochrane Controlled Trials Register as well as the Inflammatory Bowel Disease Review Group Specialized Trials Register.

The team defined refractory Crohn's disease by conventional clinical, radiological and endoscopic criteria, categorized as being active with a disease activity index more than 150.

The outcome measure was the rate of induction of remission and complete withdrawal from steroids in treatment and control groups after more than 16 weeks.

The investigators included a secondary outcome of induction of remission and reduction in steroid dose of at least 50%.

The results of the searches above were reviewed independently by two observers and relevant studies were selected according to the predefined selection criteria.

The team resolved any disagreement by consensus and used a standard data extraction form.

The same two researchers assessed the methodological quality of each trial by considering details of randomization method and whether intention-to-treat analysis was possible from the published data.

The quality of each trial was also assessed by the number of patients lost to follow-up, and whether a blinded outcome assessment was used.

In considering the appropriateness of combining results, the researchers first assessed trials according to the clinical comparability of trial protocols and study populations.

The investigators identified 5 randomized trials and these were considered inappropriate to combine because they differed with respect to participants, intervention, and outcomes.

The team found 3 small studies which employed low doses of methotrexate orally.

The pooled results of these 3 studies showed no statistically significant difference between methotrexate and placebo/control medication treated patients.

The investigators identified 1 small study which used a higher dose of intravenous/oral methotrexate that showed no statistically significant difference.

A larger study which employed a higher dose of methotrexate intramuscularly showed substantial benefit.

The researchers found adverse effects were more common with high dose intramuscular methotrexate therapy than with placebo.

Dr Alfadhli concludes, “There is evidence from a single large randomized trial on which to recommend the use of methotrexate 25 mg intramuscularly weekly for induction of remission and complete withdrawal from steroids in patients with refractory Crohn's disease.”

“Although adverse effects were more common than with placebo, they were not severe.”

“There is no evidence on which to base a recommendation for use of lower dose oral methotrexate.”

The Cochrane Database Syst Rev 2005: 2. Art. No.: CD003459.pub2. DOI: 10.1002/14651858.CD003459.pub2.
11 May 2005

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us